An approved branded medicine and a compounded preparation can use a related ingredient while remaining different products. A compounded version is not automatically a generic substitute, and a familiar brand name should not be applied to it.
This distinction matters when comparing an online price. A reader should know what is being prescribed before deciding whether two offers are comparable.
Approved products have product-specific information
Wegovy and Zepbound have official manufacturer information describing their products, approved uses, administration, and risks. Their clinical evidence concerns specific products and regimens. Use that information in a discussion with the prescriber.
Ozempic and Mounjaro are different branded products. They should not be treated as interchangeable names for every semaglutide or tirzepatide offer.
Compounding requires an individual rationale
FDA recommends compounded drugs for patients whose needs cannot be met by an approved drug. A clinician should explain why that applies and identify the actual ingredients and pharmacy. Lower price alone does not establish clinical equivalence.
A custom preparation does not undergo the same FDA premarket review. Additional ingredients, route changes, and vial instructions require their own questions.
Compare the service around the medicine
Clinical membership, pharmacy charges, consultations, supplies, and renewal terms can differ. Compare the full ongoing invoice and care access, while preserving the product distinction.
Use the GLP-1 program comparison for care models and the Ro review or CoreAge review for examples of separate-membership and advertised bundled billing.
Continue your comparison
Compare the GLP-1 programs, read the CoreAge Rx review, and use the program table to prepare questions about the complete offer.
Sources & offer details
Public information retrieved on October 1, 2026. Provider statements describe the advertised offer; they do not independently establish treatment outcomes.